Lab studies show promise for a clinical trial aimed at improving current immune therapies
System, which enables these deadly skin cancers to grow and spread.
And while new therapies have been effective in releasing the immune system's restraints to unleash the body's own cancer-fighting powers, they only work in about half of melanoma patients and often lose their potency as the cancer develops resistance.
Now a research team at the Duke Cancer Institute has found a new way to keep the immune system engaged, and is planning to test the approach in a phase 1 clinical trial. The findings are reported online in the Jan. 16 issue of the journal Immunity.
"Understanding how cancers suppress the immune system is the key to identifying more effective immuno-therapies," said Brent Hanks, M.D., Ph.D., at Duke and senior author of the study. "Our research is an important step in that direction. We've identified a new mechanism of immunotherapy resistance that appears to be reversible, potentially enhancing the effect of the therapies we now have."
Hanks and colleagues, studying genetic mouse models of melanoma and verifying the findings in human specimens, focused on immune system messengers called dendritic cells. These cells are on high alert for pathogens such as viruses, bacteria and even tumor cells, signaling the body's T-cell immune fighters into action when sensing harmful invaders.
Somehow, melanomas reprogram dendritic cells so they ignore the cancer, but this process has not been well understood. In the current study, Hanks and colleagues identified a signaling pathway within the tumor microenvironment that melanomas manipulate to silence dendritic cells.
The pathway relies on a regulatory enzyme called IDO, which plays an important role in immune suppression and is controlled by fatty acid metabolism. Hanks's team found that this metabolic pathway is what melanomas compromise, setting in motion a cascade of events that ultimately leads to the immune system tolerating the tumor cells.
Once they identified this pathway, Hanks and colleagues conducted laboratory tests of a molecule that blocks melanoma cells from going stealth, enabling the immune system to mount a direct attack while also enhancing the function of current immunotherapies such as pembrolizumab and nivolumab.
"The IDO enzyme has been a focus of research in recent years, and there are several drugs that are being investigated to target it," Hanks said. "Our research looked at how we might influence the immune suppression function of IDO by targeting it upstream, along the metabolic pathway that controls it.
"We found that this pathway regulates not only IDO but also other important components of the immune system, suggesting that blocking this pathway may be superior to targeting IDO only," Hanks said.
Hanks said a phase 1 clinical study using an existing molecule that targets this newly identified pathway is in the planning stages. It would likely explore whether the investigational drug might boost the success of current immunotherapies.
"While there is understandable excitement around new therapies that enlist the immune system to fight cancer, we are still in a situation where greater than half of patients don't respond in melanoma and the response rate is even worse in other cancer types," Hanks said. "We need to figure out why that is, and figure out how to reverse it. We're hoping this research is a good step in that direction."
In addition to Hanks, study authors include Fei Zhao, Christine Xiao, Kathy S. Evans, Tbalamayooran Theivanthiran, Nicholas DeVito, Alisha Holtzhausen, Juan Liu, Xiaojing Liu, David Boczkowski, Smita Nair and Jason W. Locasale. Hanks is working with John Strickler, M.D., also with the Duke Cancer Institute, to extend these findings into the clinic.
The study received funding support from the Duke Cancer Institute and the National Cancer Institute, part of the National Institutes of Health (1K08CA191063-01A1
Sarah Avery | EurekAlert!
Indications of Psychosis Appear in Cortical Folding
26.04.2018 | Universität Basel
GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University
Magnetic resonance imaging, or MRI, is a widely used medical tool for taking pictures of the insides of our body. One way to make MRI scans easier to read is...
At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.
Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...
Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.
Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...
University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.
Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.
Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.
Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...
13.04.2018 | Event News
12.04.2018 | Event News
09.04.2018 | Event News
26.04.2018 | Power and Electrical Engineering
26.04.2018 | Life Sciences
26.04.2018 | Power and Electrical Engineering